CD274 and non-small cell lung carcinoma: This multifunctional probiotic platform establishes a generalizable strategy for systemic delivery of living therapeutics and offers a powerful adjunct to PD‐1/PD‐L1 blockade for NSCLC and other treatment‐resistant solid tumors.